<p>&nbsp;</p> <p align="justify">Sanofi recently announced that it would group its <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target="_blank">vaccine </a>(<a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/france-pharmaceutique/entreprise-lyon-sanofi-aventis-pharmaceutique,p,130,EN.jsp" target="_blank">Sanofi Pasteur</a>) and animal health (<a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/adm1n/editor/www.aderly.com/france-vaccins-veterinaires/entreprise-lyon-merial-vaccins-veterinaires,p,124,FR.jsp" target="_blank">Merial</a>) subsidiaries in order to achieve synergies, in particular for research in infectious diseases. <strong>The headquarters will bring together 600 to 700 people in the <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/centre-recherche-et/developpement-france,p,21,EN.jsp" target="_blank">Lyon-Gerland </a>district by 2015-2016</strong>.<br></p> <p align="justify">The aim of this move is also to facilitate the creation of a <strong>Center of Excellence in infectious diseases in Lyon-Gerland</strong>, announced not long ago by the pharmaceutical giant. Some 150 researchers from both Sanofi Pasteur and Merial will work together to find more<strong> links between the human and veterinary domains</strong>, to develop drugs, animal health and human health products and vaccines.<br></p> <p align="justify">According to Alain M&#233;rieux, CEO of Institut M&#233;rieux: <em>"Sanofi is investing heavily in Lyon because the company is attracted by the science &amp; business ecosystem and has always felt very welcome here."</em> The Sanofi-Pasteur site at Marcy-l’Etoile, near Lyon, is considered one of the largest R&amp;D and vaccine production sites in the world. The company has invested more than &#8364;800 million there over the past ten years. <br></p> <p align="justify"><br></p>